India’s central drug regulator flagged 169 medicine samples as Not of Standard Quality during April inspections, while one batch of Ursodeoxycholic Acid was identified as potentially spurious. Authorities said the findings are part of routine nationwide drug surveillance and investigations into the suspicious batch are ongoing.